N-(2-aminoethyl)-4-<(methylsulfonyl)amino>benzamide | 107726-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-aminoethyl)-4-<(methylsulfonyl)amino>benzamide
• 英文别名: N-(2-aminoethyl)-4-[(methylsulfonyl)amino]benzamide；N-(2-aminoethyl)-4-(methanesulfonamido)benzamide
• CAS: 107726-50-1
• 化学式: C₁₀H₁₅N₃O₃S
• 分子量: 257.313
• InChiKey: HBBILOXPORQCLY-UHFFFAOYSA-N

物化性质

• 熔点：
  184.5-186.0 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(1-萘氧基)-1,2-环氧丙烷 、 N-(2-aminoethyl)-4-<(methylsulfonyl)amino>benzamide 以 甲醇 、 水 为溶剂， 反应 18.0h， 以22%的产率得到N-[2-[(2-hydroxy-3-naphthalen-1-yloxypropyl)amino]ethyl]-4-(methanesulfonamido)benzamide
  参考文献：
  名称：

  Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

  摘要：

  Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (beta-blocking) effects with use of in vitro and in vivo models. Structure-activity relationships are discussed for a series of 30 compounds. A number of these compounds prolonged the action potential duration at 95% repolarization of isolated canine cardiac Purkinje fibers by 20% (C20APD95) at concentrations of less than 1.0 microM, with no significant effects on cardiac conduction. beta-Adrenergic receptor binding studies showed that some of these compounds were 2-20 times more potent for cardiac beta 1 receptors than for beta 2 receptors. In particular, compounds 32, 41, 1, and especially (S)-1 were found to be orally active class III agents in anesthetized mongrel dogs (1 or 3 mg/kg, id) and efficacious at suppressing programmed electrical stimulation induced arrhythmias in halothane-anesthetized dogs. The profile of these compounds was similar to that found for sotalol. Compound (S)-1, which was more potent than sotalol in the PES study and equieffective in the halothane/epinephrine dog model, is being investigated further as a combined class III/II antiarrhythmic agent.

  DOI：

  10.1021/jm00172a033
• 作为产物：
  描述：

  4-(甲基磺酰胺)苯甲酸甲酯 、 乙二胺 反应 5.0h， 以73%的产率得到N-(2-aminoethyl)-4-<(methylsulfonyl)amino>benzamide
  参考文献：
  名称：

  Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

  摘要：

  Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (beta-blocking) effects with use of in vitro and in vivo models. Structure-activity relationships are discussed for a series of 30 compounds. A number of these compounds prolonged the action potential duration at 95% repolarization of isolated canine cardiac Purkinje fibers by 20% (C20APD95) at concentrations of less than 1.0 microM, with no significant effects on cardiac conduction. beta-Adrenergic receptor binding studies showed that some of these compounds were 2-20 times more potent for cardiac beta 1 receptors than for beta 2 receptors. In particular, compounds 32, 41, 1, and especially (S)-1 were found to be orally active class III agents in anesthetized mongrel dogs (1 or 3 mg/kg, id) and efficacious at suppressing programmed electrical stimulation induced arrhythmias in halothane-anesthetized dogs. The profile of these compounds was similar to that found for sotalol. Compound (S)-1, which was more potent than sotalol in the PES study and equieffective in the halothane/epinephrine dog model, is being investigated further as a combined class III/II antiarrhythmic agent.

  DOI：

  10.1021/jm00172a033

文献信息

• Substituted sulfonamidobenzamides and method of treating arrhythmias
  申请人：Schering A.G.

  公开号：US04629739A1

  公开（公告）日：1986-12-16

  Novel substituted sulfonamidobenzamides are described as useful antiarrhythmic agents. Their use in the treatment of cardiac arrhythmias, especially re-entrant arrhythmias, via the prolongation of the action potential of cardiac tissue is provided. Pharmaceutical formulations containing such compounds are also disclosed.

  小说替代磺胺基苯甲酰胺被描述为有用的抗心律失常药物。它们通过延长心脏组织的动作电位来治疗心律失常，特别是再进入性心律失常。还公开了含有这些化合物的药物制剂。
• LIS, RANDALL;MORGAN, THOMAS K. (JR);MARISCA, ANTHONY J.;GOMEZ, ROBERT P.;+, J. MED. CHEM., 33,(1990) N0, C. 2883-2891
  作者：LIS, RANDALL、MORGAN, THOMAS K. (JR)、MARISCA, ANTHONY J.、GOMEZ, ROBERT P.、+

  DOI：——

  日期：——
• MAO-B INHIBITORS USEFUL FOR TREATING OBESITY
  申请人：McElroy Francis John

  公开号：US20070015734A1

  公开（公告）日：2007-01-18

  The invention provides novel compounds of formula I: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
• US4629739A
  申请人：——

  公开号：US4629739A

  公开（公告）日：1986-12-16
• US8138209B2
  申请人：——

  公开号：US8138209B2

  公开（公告）日：2012-03-20